TKNO
What one share of Alpha Teknova holds
In Vitro and In Vivo Diagnostic Substances
Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.
Alpha Teknova’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.82 |
|---|---|
| Profit | −$0.31 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.14 |
| Cash and investments | $0.11 |
| Debt | $0.25 |
| Book value | $1.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $8.23 | $0.16 | $1.44 | −$0.78 | — | $4.66 |
| 2021 | $2.29 | −$0.61 | $1.24 | −$1.80 | — | $5.11 |
| 2022 | $1.47 | −$1.69 | $1.00 | −$1.98 | — | $3.54 |
| 2023 | $1.15 | −$1.16 | $0.25 | −$0.84 | — | $2.21 |
| 2024 | $0.81 | −$0.57 | $0.02 | −$0.29 | — | $1.54 |
| 2025 | $0.76 | −$0.32 | $0.02 | −$0.18 | — | $1.28 |